On Thursday, Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), gained 4.55% to $2.53.
Advanced Micro Devices, unveiled innovation in heterogeneous high performance computing (HPC) by delivering more than 1.5 petaFLOPS of AMD FirePro™ S9150 server GPU performance for the Next Generation Sequencing Centre (NGSC) at the Centre of New Technologies, University of Warsaw in support of bioinformatics research related to next generation sequencing (NGS) studies. The new ORION cluster features 150 Dell PowerEdge R730 servers with two AMD FirePro S9150 server GPUs, for a total GPU peak of 1.52 petaFLOPS single precision and 0.76 petaFLOPS double precision performance1. The energy-efficient cluster enables high speed and efficient calculations for genomic data, applicable to a range of genomics and bioinformatics studies, using a fast and power efficient OpenCL™ implementation for research applications.
NGSC at the Centre of New Technologies, University of Warsaw, located in Warsaw, Poland, is a research facility for top-of-the-line genomics and bioinformatics studies in biology, medicine, diagnostics and therapy. The ORION cluster was designed and built for storing and processing of huge amount of data generated by the sequencers accessible in the Centre. NGSC conducts a variety of genomics projects in numerous collaborations by providing NGS technology to academia and industry. Researches from around the world are using this facility to perform NGS (e.g. genomic, metagenomic, transcriptomic, epigenetic) experiments that assist them make fascinating research discoveries. Many of bioinformatics studies conducted at NGSC require large computational power, which is delivered by the ORION cluster.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Shares of Ares Capital Corporation (NASDAQ:ARCC), inclined 0.61% to $16.58, during its last trading session.
Ares Capital Corporation, declared that it extended the maturity and reduced pricing on its existing $400 million revolving funding facility with Sumitomo Mitsui Banking Corporation. ARCC extended the reinvestment period by one year to September 14, 2017 and stated maturity by one year to September 14, 2022. The stated interest rate on the facility was changed from LIBOR plus 2.00% to either LIBOR plus 1.75% or LIBOR plus 2.00%, determined based on usage levels.
“The extension and favorable pricing changes shows the confidence our lenders have in ARCC. We have built a strong relationship with Sumitomo Mitsui Banking Corporation and appreciate their support in assisting us to continue to lower the cost of our revolving debt capital,” stated Penni Roll, Chief Financial Officer of Ares Capital Corporation.
In addition to this $400 million revolving funding facility, Ares Capital Corporation, counting through a wholly owned financing partner, has two other revolving credit facilities with total commitments of $1.8 billion, bringing total revolving credit capacity to about $2.2 billion (subject to borrowing base and leverage restrictions).
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing.
Finally, Monsanto Company (NYSE:MON), ended its last trade with 0.64% gain, and closed at $108.35.
On June 24, Monsanto Company, delivered solid results for the third quarter and reaffirmed its guidance estimates for fiscal year 2015 earnings per share and free cash flow. In reporting earnings results, the company highlighted continued progress on several key milestones related to the company’s long-term growth drivers and pursuit of the next evolution in agriculture. Executives also reiterated Monsanto’s vision and planned rationale for the Syngenta proposal to create a new company that would provide a comprehensive portfolio of integrated solutions to assist farmers around the world address current and future agricultural, environmental and sustainability challenges.
Results of Operations
Net sales for the fiscal year 2015 third quarter raised over the preceding year’s third quarter to $4.6 billion, with gross profit for the quarter also increasing over the preceding year period to $2.7 billion. For the first nine months, net sales were $12.6 billion and gross profit $7.2 billion.
The third-quarter results were above the range outlined at the company’s second-quarter earnings, with the performance reflecting the change in the U.S. Channel® seed brand business model increasing gross profit in the third quarter, in addition to strong Agricultural Productivity segment performance due to the recent agreement with Scotts Miracle Gro.
Selling, general and administrative (SG&A) costs were $718 million and R&D expenses were $374 million for the third quarter. Year-to-date, total operating expenses were flat, effectively absorbing more than $100 million inflationary enhances and a ramp in spend in the company’s Climate and biological platforms to support the long-term growth prospects for these opportunities.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
